REG - Angle PLC - ANGLE notice of interim results

AngleAnnouncement

15/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230815:nRSO2793Ja&default-theme=true

RNS Number : 2793J  Angle PLC  15 August 2023

 For immediate release  15 August 2023

 

ANGLE plc ("the Company")

 

Notice of Interim Results and Webcast

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative CTC diagnostic solutions for the research and diagnostic oncology
market, will be releasing its interim results for the six months ended 30 June
2023 on Thursday 7 September 2023.

 

A meeting for analysts will be held at 11:00 am BST on Thursday 7 September
2023 at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street,
London EC1A 4HD.

 

A live webcast of the analyst meeting can be accessed via ANGLE's Investor
Centre page, https://angleplc.com/investor-relations/corporate-presentations/
(https://angleplc.com/investor-relations/corporate-presentations/) , with
Q&A participation reserved for analysts only. Please register in advance
and log on to the webcast approximately 5 minutes before 11:00 am on the day
of the results. A recording of the webcast will be made available on ANGLE's
website following the results meeting.

 

For further information:

 

 ANGLE plc                                   +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Andrew Holder, Head of Investor Relations

 Berenberg (NOMAD and Joint Broker)          +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 Jefferies (Joint Broker)                    +44 (0) 20 7029 8000

 Thomas Bective, Shaam Vora

 FTI Consulting

 Simon Conway, Ciara Martin                  +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                    +1 (212) 850 5624

 

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative CTC diagnostic
solutions for the research and diagnostic oncology market using a simple blood
sample. ANGLE's FDA cleared and patent protected circulating tumor cell (CTC)
harvesting technology known as the Parsortix(®) system enables complete
analysis of the sample including whole cell imaging and proteomic analysis and
full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix(®) system and associated
consumables. The clinical services business is offered through ANGLE's
GCP-compliant laboratories in the UK and the United States.  Services include
custom made assay development and clinical trial testing for pharma.

 

Over 80 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORPIMFTMTTBBRJ